{
    "output": [
        [
            "Akebia Therapeutics Inc.",
            "ORG",
            "Announce",
            "Positive Results",
            "CONCEPT"
        ],
        [
            "Akebia Therapeutics Inc.",
            "ORG",
            "Operate_In",
            "Pharmaceutical Industry",
            "SECTOR"
        ],
        [
            "Vadadustat",
            "PRODUCT",
            "Relate_To",
            "Anemia Associated with Dialysis-Dependent Chronic Kidney Disease",
            "CONCEPT"
        ],
        [
            "Vadadustat",
            "PRODUCT",
            "Participates_In",
            "Phase 2 Study",
            "EVENT"
        ],
        [
            "Vadadustat",
            "PRODUCT",
            "Impact",
            "Japanese Patients",
            "GPE"
        ],
        [
            "Vadadustat 150MG",
            "PRODUCT",
            "Positive_Impact_On",
            "Placebo",
            "PRODUCT"
        ],
        [
            "Vadadustat 300MG",
            "PRODUCT",
            "Positive_Impact_On",
            "Placebo",
            "PRODUCT"
        ],
        [
            "Vadadustat 600MG",
            "PRODUCT",
            "Positive_Impact_On",
            "Placebo",
            "PRODUCT"
        ],
        [
            "Phase 3 Study",
            "EVENT",
            "Operate_In",
            "Non-Dialysis Patients in Japan",
            "GPE"
        ],
        [
            "Phase 3 Study",
            "EVENT",
            "Operate_In",
            "Dialysis Patients",
            "GPE"
        ],
        [
            "Serious Adverse Events",
            "CONCEPT",
            "Relate_To",
            "Prior Studies",
            "CONCEPT"
        ],
        [
            "No Deaths",
            "CONCEPT",
            "Relate_To",
            "Reported",
            "CONCEPT"
        ]
    ]
}